FDA is to assess data linking type 2 diabetes drugs with pancreatitisBMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f1808 (Published 19 March 2013) Cite this as: BMJ 2013;346:f1808
- Deborah Cohen
The US Food and Drug Administration has taken the unusual stance of announcing that it will evaluate data provided to it by a group of unnamed independent researchers indicating that glucagon-like peptide-1 (GLP-1) based drugs used in type 2 diabetes could raise the risk of pancreatitis and precancerous pancreatic lesions.
According to the FDA’s statement the data indicate an increased risk of pancreatitis and cellular changes called pancreatic duct metaplasia in people with type 2 diabetes who are treated with the drugs, which are incretin mimetics.1 However, the FDA emphasized that it has not reached any new conclusions about the safety of the drugs, nor has it “concluded …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial